Valuation: Geron Corporation

Market Cap 944M 816M 767M 697M 1.31B 90.31B 1.33B 8.98B 3.51B 45.22B 3.55B 3.47B 150B P/E 2026 *
-35x
P/E 2027 * 21.6x
Enterprise Value 944M 816M 767M 697M 1.31B 90.31B 1.33B 8.98B 3.51B 45.22B 3.55B 3.47B 150B EV / Sales 2026 *
4x
EV / Sales 2027 * 2.76x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-4.23%
1 week-0.68%
Current month+13.95%
1 month+3.52%
3 months+13.95%
6 months-10.91%
Current year+11.36%
1 week 1.44
Extreme 1.44
1.65
1 month 1.22
Extreme 1.22
1.65
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap.
30/6/26 Free

Director

6,103 0.0010%
17/2/26 Fiscal year

Chief Financial Officer

1,724,855 0.2702%
17/2/26 Free

Chief Technology Officer

2,220,000 0.3478%
Change 5-day change 1-year change 3-year change Capi.($)
-4.23%-0.68%+1.38%-45.56% 944M
-1.90%+2.85%+62.82%+104.39% 70.07B
+9.12%+3.90%+38.98%+74.53% 52.87B
-2.05%-5.61%-3.18%+449.22% 27.02B
+2.44%+0.35%+49.29%+12.19% 23.61B
+1.05%-0.62%-18.00%-13.77% 23.38B
+3.81%+20.97%+266.37%+477.93% 19.43B
+2.05%+1.40%+35.36%-19.47% 18.75B
+0.77%-0.76%+17.39%+569.86% 15.85B
+1.24%-5.23%+33.75%+140.34% 12.7B
Average +1.24%-0.87%+48.42%+174.97% 26.46B
Weighted average by Cap. +1.94%-1.40%+51.63%+162.70%

Financials

2026 *2027 *
Net sales 236M 204M 192M 174M 328M 22.59B 333M 2.25B 879M 11.31B 887M 868M 37.6B 342M 295M 278M 252M 475M 32.7B 482M 3.25B 1.27B 16.37B 1.28B 1.26B 54.42B
Net income -27.18M -23.48M -22.06M -20.06M -37.72M -2.6B -38.34M -258M -101M -1.3B -102M -99.84M -4.33B 50.14M 43.31M 40.7M 37.01M 69.59M 4.79B 70.73M 477M 186M 2.4B 188M 184M 7.98B
Net Debt - -
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
14/08/26 USD 1.470 -4.23% 11,157,986
13/08/26 USD 1.535 -2.23% 5,633,568
12/08/26 USD 1.570 -3.68% 10,202,342
11/08/26 USD 1.630 +10.14% 12,716,754
10/08/26 USD 1.480 0.00% 5,641,719
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.470USD
Average target price
4.250USD
Spread / Average Target
+189.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock